Clinical trial · Observational
A Retrospective Chart Review Study of Gene-Eden-VIR/Novirin
NCT02715752CI-TRIAL-00021912completedClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This study measured the changes in health-related complaints by analyzing charts of individuals, who are infected with a latent virus, who have used Gene-Eden-VIR/Novirin.
Conditions
Conditions (5)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Cytomegalovirus Infections | — | UNRESOLVED | — |
| Epstein-Barr Virus Infections | — | UNRESOLVED | — |
| Herpes Simplex Infections | — | UNRESOLVED | — |
| Human Papillomavirus | — | UNRESOLVED | — |
| Varicella-zoster Virus Infection | — | UNRESOLVED | — |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Gene-Eden-VIR/Novirin | Dietary Supplement | — | UNRESOLVED |
Design
Arms and outcomes
Arms (5)
- label
- Herpes Simplex Virus Infection
- description
- Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
- interventionNames
- Dietary Supplement: Gene-Eden-VIR/Novirin
- label
- Human Papillomavirus Infection
- description
- Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
- interventionNames
- Dietary Supplement: Gene-Eden-VIR/Novirin
- label
- Epstein-Barr Virus Infection
- description
- Gene-Eden-VIR/Novirin, oral, 1-4 capsules per day, 12 months
- interventionNames
- Dietary Supplement: Gene-Eden-VIR/Novirin
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Latent viral infection with either HSV, HPV, VZV, EBV, or CMV * Taking Gene-Eden-VIR/Novirin Exclusion Criteria: * Use of other antiviral treatments
References
Publications (1)
- DERIVEDPolansky H, Itzkovitz E, Javaherian A. Clinical study of Gene-Eden-VIR/Novirin in genital herpes: suppressive treatment safely decreases the duration of outbreaks in both severe and mild cases. Clin Transl Med. 2016 Dec;5(1):40. doi: 10.1186/s40169-016-0121-6. Epub 2016 Oct 20. PMID 27766602